399. Multi-centre observational study on epidemiology, treatment and outcome of Mucormycosis in India
Session: Poster Abstract Session: Fungal Disease: Management and Outcomes
Thursday, October 4, 2018
Room: S Poster Hall
  • FISF Mucor study Poster.pdf (3.1 MB)
  • Background: Though the rise in number of mucormycosis cases has been reported globally, the rise in India is alarming especially in uncontrolled diabetics. However, multiple gaps exist in the understanding of the disease in this country.

    Methods: Objectives: To describe the epidemiology, diagnosis, treatment practices and outcome of mucormycosis in India.

    A single arm prospective observational study was conducted in the network of 17 tertiary care centres across India during April 2016 through September 2017. All consecutive proven mucormycosis patients were enrolled in this study. Clinical data including risk factors, investigations and treatment were collected. All isolates and histopathological specimens were sent to Mycology Reference Laboratory at Chandigarh for final identification (phenotypic and sequencing) and drug susceptibility testing.

    Results: A total of 474 cases were enrolled between the study period. Rhino-orbito-cerebral mucormycosis was common (42.7%) presentation with 22.8% patients had brain involvement, followed by pulmonary (14.6%), cutaneous (11.8%), isolated renal (3.9%) and intraabdominal (2.8%) mucormycosis. The underlying disease or predisposing factors were noted in 79.7% cases (84.9% diabetes mellitus, 12.9% steroids, 10.3% trauma or history of surgery, 9.7% malignancy and 9.2% transplant). The most common agents isolated were Rhizopus species (75.9%, R. arrhizus [74.3%] & R. homothallicus [6.7%]) followed by Apophysomyces variabilis (7.4%), Mucor species (6%), & Lichtheimia corymbifera (4%). The patients were managed by medical therapy in 82.8%, surgery in 56.8% while 51.7 % received combined medical and surgical management. Amphotericin B (96.8%) either lipid formulations (65.7%) or conventional form (39.1%) was the common antifungal used. The mortality of patients was 30.4% of which 80.3% patients died within 6 weeks of their diagnosis. 24.3% patients left hospital against medical advice while 50.1% survived.

    Conclusion: Rhino-orbital-cerebral mucormysosis in uncontrolled diabetics is common presentation in India. R. arrhizus followed by A. variabilis are common species isolated from those patients. Survival was noted only in half of the patients despite increased awareness and diagnosis.

    Atul Patel, MD, FIDSA1,2, Harsimran Kaur, MD3, Immaculata Xess, MD4, Joy S Michael, MD, FRC(Path)5, Jayanthi Savio, MD6, Shivaprakash Rudramurthy, MD3, Rakesh Singh, MD7, Prakash Shastri, MD8, Pamidimukkala Umabala, MD9, Raman Sardana, MD10, Anupama Jyoti Kindo, MD11, Malini Capoor, MD12, Sangeetha Mohan, MD13 and Arunaloke Chakrabarti, MD, FIDSA14, (1)Infectious Diseases, Veda. Inst. of Med.Sci, Ahmedabad, India, (2)Department of Internal Medicine, University of South Florida, Tampa, FL, (3)Department of Microbiology, PGIMER, Chandigarh, India, (4)Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India, (5)Clinical Microbiology, Professor, Vellore, India, (6)St. John's Medical College Hospital, Banaglore, India, (7)Department of Microbiology, JIPMER, Pondicherry, India, (8)Intensive Care Medicine, Sir Gangaram Hospital, New Delhi, India, (9)Department of Microbiology, Nijam Institute of Medical Sciences, Hyderabad, India, (10)Department of Microbiology, Indraprastha Apollo Hospital, New Delhi, India, (11)Department of Microbiology, Sri Ramachandra Medical College, Chennai, India, (12)Department of Microbiology, Safdarjung Hospital, New Delhi, India, (13)Christian Medical College, Ludhiana, India, (14)Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India


    A. Patel, None

    H. Kaur, None

    I. Xess, None

    J. S Michael, None

    J. Savio, None

    S. Rudramurthy, None

    R. Singh, None

    P. Shastri, None

    P. Umabala, None

    R. Sardana, None

    A. Jyoti Kindo, None

    M. Capoor, None

    S. Mohan, None

    A. Chakrabarti, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.